Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | PNP | P00491 | 2/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | EIF4E | P06730 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15728301 | 1.00 | P2RY2 (0.45) | P2RY2P2RY4NT5EPOLBTAS1R3 | |
| SCHEMBL12477755 | 0.94 | NT5E (0.42) | P2RY2P2RY4NT5EPOLBTAS1R3 | |
| SCHEMBL15728300 | 0.92 | P2RY2 (0.56) | P2RY2P2RY4NT5EPOLBPNP | |
| SCHEMBL12477717 | 0.92 | P2RY2 (0.56) | P2RY2P2RY4NT5EPOLBPNP | |
| SCHEMBL15725567 | 0.86 | PNP (0.53) | PNPALDH1A1 | |
| SCHEMBL12477821 | 0.86 | PNP (0.53) | PNPALDH1A1 | |
| SCHEMBL12477825 | 0.86 | PNP (0.53) | PNPALDH1A1 | |
| SCHEMBL1577230 | 0.84 | NT5E (0.57) | P2RY2P2RY4NT5EPOLBTAS1R3 | |
| SCHEMBL12939473 | 0.84 | NT5E (0.57) | P2RY2P2RY4NT5EPOLBTAS1R3 | |
| SCHEMBL15468735 | 0.84 | NT5E (0.57) | P2RY2P2RY4NT5EPOLBTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351989-B2 | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | INHIBITEX, INC. (US) | 2016-05-31 | — | — | US | claimed |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | US | claimed |
| EP-2658857-B1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX INC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2658857-B1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9351989-B2 | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | INHIBITEX, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351989-B2 | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | INHIBITEX, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351989-B2 | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | INHIBITEX, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| EP-2658857-A2 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | Inhibitex, Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012092484-A2 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX, INC. (US) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | PNP, UMPS, UPP1 | P2RY2 39/4885P2RY4 22/4885NT5E 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.